Arvinas to out-license ARV-806 after completing Phase 1 dose escalation

ARVINAS, INC.

Completed dose escalation enrollment for ARV-806 Phase 1 trial in KRAS G12D solid tumors.
Will complete monotherapy dose escalation and share clinical data in 2026.
Plans to seek out-licensing agreement for any additional ARV-806 trials.
Cash, equivalents and marketable securities as of March 31, 2026 fund operations into H2 2028.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-26-039818
form_type: 8-K
ticker: ARVN
cik: 0001655759
company_name: ARVINAS, INC.
filed_at: 2026-06-02T20:39:40+00:00
discovered_at: 2026-06-02T20:41:00.246164+00:00
generated_at: 2026-06-02T20:41:08.859678+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-26-039818
json_url: https://secwatch.observer/filing/0001628280-26-039818.json
markdown_url: https://secwatch.observer/filing/0001628280-26-039818.md
text_url: https://secwatch.observer/filing/0001628280-26-039818.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1655759/000162828026039818/0001628280-26-039818-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1655759/000162828026039818/arvn-20260602.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

MBOT

Microbot Medical secures first North Carolina customer for LIBERTY robotic system

Microbot Medical Inc. June 2, 2026, 8:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NRXP

NRx Pharmaceuticals proposes public offering of common stock; terms not set

NRX Pharmaceuticals, Inc. June 2, 2026, 5:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XMTR

Xometry announces public offering of 2.65M shares at $85.00; expected net proceeds $215.2M

Xometry, Inc. June 2, 2026, 5:26 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Pacific Oak Strategic Opportunity REIT, Inc.

Net loss $20.5M, going concern doubt for Pacific Oak Strategic Opportunity REIT subsidiary

Pacific Oak Strategic Opportunity REIT, Inc. June 2, 2026, 5:09 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CEG

Constellation Energy secondary offering of 11M shares with concurrent $558M share repurchase

Constellation Energy Corp June 2, 2026, 4:15 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

LendingClub to transfer NYSE listing to Nasdaq, new ticker HAPN

LendingClub Corp June 2, 2026, 4:11 PM ET other_material Items 3.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JAGX

Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8

Jaguar Health, Inc. June 2, 2026, 4:10 PM ET other_material Items 1.01, 3.02, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001628280-26-039818

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.